ful planning every year to ensure a sufficient supply of fertile eggs [9] .
Recurrent annual influenza vaccine shortages experienced in the United States demonstrate the need for additional technologies to facilitate the timely production of influenza vaccines [8] . For egg-based vaccines, production cannot be scaled up at short notice to meet changes in demand or in serotype selection. New cell line substrates for the manufacture of inactivated influenza vaccine may alleviate the limitations of egg-based vaccines [10] .
New research has focused on the development of cell culturederived vaccine production technology using either mammalian cell lines for viruses or insect cells for recombinant antigens [11] [12] [13] [14] . Production in mammalian cell lines offers significant advantages in the manufacturing process over egg-based production, because it allows more flexibility, faster production, and adequate availability of substrate for virus growth [15] , eliminating reliance on the supply of embryonated chicken eggs [13, [16] [17] [18] [19] . The virus also remains antigenically unchanged in cell lines, whereas it may become slightly modified during egg incubation [20] . Egg proteins are not present in cell culturederived vaccines; therefore, such vaccines will offer a muchneeded alternative for individuals with egg allergies [13] .
A specific cell line cloned from Madin-Darby canine kidney (MDCK) tissue has been developed for the propagation of influenza viruses. The MDCK cell line originated from canine kidney in 1958 and is a well-known and accepted cell substrate for the isolation and propagation of a wide variety of human influenza viruses [16] . This cell line has been adapted to grow in suspension and produces high viral yields quickly [21, 22] . The influenza viruses are propagated in high-concentration cell cultures and then harvested to produce the investigational cell culture-derived influenza vaccine (CCIV).
With any vaccine produced using new technologies, it is important to demonstrate not only the immunogenicity but also the safety and reactogenicity of the vaccine. The clinical results reported here are the first from a series designed to evaluate the safety, reactogenicity, and immunogenicity of CCIV in comparison to a US-licensed egg-based trivalent inactivated influenza vaccine (TIV). . Enrollment occurred during the 2 weeks commencing 24 October 2005, and subjects were followed up for 6 months. The study protocol was reviewed and approved by a central investigational review board. Written informed consent, in compliance with the Declaration of Helsinki, was obtained from each subject before study entry.
METHODS

Study
Study population. Healthy adult subjects 18 to !50 years of age were enrolled. Exclusion criteria included serious disease, history of hypersensitivity to eggs or other study-vaccine components, impaired or altered immune function, laboratory-confirmed influenza, vaccination against influenza within 6 months before enrollment, receipt of any investigational agent within 90 days before enrollment or before completing the follow-up period in another study, any acute respiratory disease or infection requiring systemic antibiotics or antiviral therapy, and fever within 3 days of enrollment. Women who were pregnant or unwilling to use adequate contraception for 6 weeks after vaccination were also excluded.
Randomization. To ensure an equal representation across the age categories, subjects were stratified at each site into 3 age groups (18 to р30, 31 to 40, and 41 to !50 years of age), and ∼200 subjects were enrolled in each group. Each subject was assigned a 7-digit subject number. Randomization lists were prepared by the Novartis Biostatistics and Clinical Data Management Department or a designee and were provided to the investigator for use by the unblinded study personnel only.
Assessments. The safety and reactogenicity of the 2 vaccines were assessed by evaluating immediate reactions within 30 minutes of vaccination and solicited indicators of reactogenicity and all adverse events (AEs) for 7 days after vaccination. Solicited local reactions included ecchymosis, erythema, induration, swelling, and pain. Solicited systemic reactions included chills, malaise, myalgia, arthralgia, headache, sweating, fatigue, nausea, fever (temperature, у38ЊC), and ocular and respiratory symptoms (cough, wheezing, chest tightness, difficulty breathing, sore throat, facial edema, and red eyes). All serious AEs and those AEs resulting in withdrawal from the study were recorded during the entire study period (180 days). A subset of 120 subjects underwent additional testing for serum chemistry and complete blood count on day 1 before vaccination and on day 8 after vaccination. All clinically significant laboratory values that deviated from the normal range were to be reported.
On day 1 before vaccination and on day 22 after, blood was collected for serologic testing (range, day 19-30; 80% of blood draws occurred between days 21 and 25). The immunogenicity of the 2 vaccines was evaluated using the hemagglutination inhibition (HI) assay. Primary assessments used egg-derived antigens in the HI assay, whereas secondary assessments used cell-derived antigens, consistent with a previous study [23] . All assays measured antibodies against each strain (A/H1N1, A/H3N2, and B).
For assessment of immunogenicity, the noninferiority of CCIV to TIV for each of the 3 virus strains was assessed on the basis of the ratio of postvaccination (day 22) geometric mean titers (GMTs) between the 2 vaccines (CCIV:TIV). The main secondary measures of immunogenicity were seroprotection rate (defined as the percentage of subjects with an HI titer у40) at baseline and on day 22 and seroconversion rate (defined as the percentage of subjects with either a prevaccination HI titer !10 and a postvaccination HI titer у40 or a prevaccination HI titer у10 and a у4-fold increase in postvaccination HI titer).
Statistical methods and analysis. Sample size and statistical power considerations were based on the demonstration of noninferiority of CCIV to TIV in terms of the postvaccination (day 22) GMTs. Specifically, the criterion for noninferiority that was agreed on with the Center for Biologics Evaluation and Research (CBER) for each of the 3 strains was a lower limit of the 95% confidence interval (CI) for the ratio (CCIV:TIV) of day 22 GMTs 10.5. Data were analyzed using an analysis of covariance model, with factors for vaccine group and study center, adjusted for baseline titers as a covariate.
In addition, vaccine group differences in the percentages of subjects who achieved seroprotection (HI titer, у40) were assessed using the x 2 test, as were vaccine group differences in the percentages of subjects who achieved seroconversion from before to after (day 22) vaccination.
RESULTS
Subjects.
Safety analyses were performed for all 613 adult subjects enrolled. Three subjects were excluded from the immunogenicity analysis: 1 subject (TIV) was lost to follow-up on day 3; 1 subject (CCIV) did not provide a blood sample; and 1 subject (TIV) received the wrong vaccine (figure 1). Age and other baseline characteristics were similarly distributed between the 2 vaccine groups (table 1) . Safety and reactogenicity. No clinically relevant differences in the safety and reactogenicity profiles of the 2 vaccines were observed (figure 2). Solicited local or systemic reactions were reported as mostly mild or moderate in both vaccine groups. Overall, comparing CCIV and TIV, local reactions were reported by 54% and 61% of subjects, respectively ( ), P p .104 and systemic reactions were reported by 58% of subjects in each group ( ). The most common local reaction re-P p .877 ported was pain at the injection site (50% and 56%, respectively). The only statistically significant difference between the vaccine groups for local reactions was in the percentage of subjects who reported ecchymosis, with fewer reports following CCIV than TIV vaccination (4% and 9%, respectively; P p ) (table 2) . The most common systemic reactions reported .017 in the CCIV and TIV groups were headache (35% and 40%, respectively) and malaise (25% and 24%, respectively). The only significant difference between the vaccine groups for systemic reactions was a lower frequency of subjects reporting chills in the CCIV group than in the TIV group (5% and 9%, respectively; ) (table 2) . P p .044 No differences between the 2 vaccine groups were reported for ocular or respiratory symptoms. The most commonly reported ocular and respiratory symptoms by the CCIV and TIV groups were cough (8% and 12%, respectively) and sore throat (17% and 15%, respectively). All other symptoms were reported infrequently.
Fewer recipients of CCIV than TIV reported any AE (16% and 25%, respectively;
) and any AE considered pos-P p .009 sibly or probably vaccine related (7% and 10%, respectively;
). Nearly all unsolicited AEs (90%) that were consid-P p .169 ered possibly or probably vaccine related were classified as mild or moderate, as were nearly all other unsolicited AEs (86%). No AEs resulted in withdrawal from the study. Eight serious AEs were reported, 3 in the CCIV group (for cellulitis, n p ; for influenza, ; and for hypertension, ) and 5 in 1 n p 1 n p 1 the TIV group (for cholelithiasis, ; for influenza, ; n p 1 n p 2 for overdose, ; and for nasal-septal operation, ); n p 1 n p 1 none were considered related to the study vaccine. No deaths were reported.
There were no clinically significant abnormalities in the individual laboratory test values for either vaccine group.
Immunogenicity. Postvaccination immunogenicity results were similar whether egg-derived or cell culture-derived test antigens were used. The results reported in this article are predominantly based on the HI assay using egg-derived test antigens.
GMTs were equivalent for the A/H1N1 strain, were higher in the TIV group for the A/H3N2 strain, and were higher in the CCIV group for the B strain (table 3) . For each of the 3 virus strains contained in the vaccines, the lower limit of the 2-sided 95% CI for the ratio between the GMTs of the vaccine groups on day 22 was 10.5, demonstrating the noninferiority of CCIV to TIV as defined in the protocol (table 3 and figure 3) .
For the CCIV and TIV groups, respectively, seroprotection rates (95% CI) were 96% (94%-98%) and 98% (96%-99%) against the A/H1N1 strain, 91% (87%-94%) and 96% (93%-98%) against the A/H3N2 strain, and 94% (91%-96%) and 93% (89%-95%) against the B strain. The only statistically significant difference was against the A/H3N2 strain (TIV was greater than CCIV; the 95% CI of the vaccine group difference did not include 0). This statistically significant difference was also observed before vaccination, on day 1 of the study, when seroprotection rates against the A/H3N2 strain were 14% (11%-19%) and 22% (18%-28%) for the CCIV and TIV groups, respectively. Nonetheless, in both vaccine groups the percentage of subjects achieving seroprotection by day 22 fulfilled the CBER criterion, as the lower limit of the 2-sided 95% CI exceeded 70% for all 3 virus strains ( figure 4A ).
For the CCIV and TIV groups, respectively, seroconversion rates (95% CI) were 62% (57%-68%) and 65% (59%-70%) against the A/H1N1 strain, 85% (81%-89%) and 92% (88%-95%) against the A/H3N2 strain, and 77% (72%-81%) and 76% (70%-80%) against the B strain. The only statistically significant difference was against the A/H3N2 strain (TIV was greater than CCIV; the 95% CI of the vaccine group difference did not include 0) when egg-derived antigens were used in the HI assay. When the assay was repeated using cell-derived antigens, the difference between the CCIV and TIV groups was not statistically significant (point estimate of difference, Ϫ1% [89% vs 90%]; 95% CI, Ϫ6% to 4%) (data not shown). In both vaccine groups, the percentage of subjects achieving seroconversion by day 22 fulfilled the CBER criterion, as the lower limit of the 2-sided 95% CI exceeded 40% for all 3 virus strains (figure 4B).
DISCUSSION
This phase 2 study demonstrated that CCIV is at least as well tolerated and immunogenic as a US-licensed egg-based TIV. In both groups, pain at the injection site was the most frequent local reaction, reported in more than half of subjects in both vaccine groups. Ecchymosis and chills were reported by a greater number of subjects in the TIV group than in the CCIV group. No difference was observed in the frequency of systemic AEs. Most unsolicited AEs were classified as mild or moderate in severity.
Both CCIV and the egg-based TIV were highly immunogenic in all subjects against all 3 virus strains, as determined by evaluation of GMTs, seroprotection rates, and seroconversion rates. The noninferiority of GMTs after CCIV compared with TIV administration was demonstrated for each of the 3 virus strains. Furthermore, GMTs in all groups were robust (1135), so the clinical significance of any difference between particular strains is negligible. In addition, on day 22 each of the 3 virus strains in CCIV and TIV induced responses that met the criteria set forth by CBER in the United States, as well as by the Committee for Medicinal Products for Human Use (CHMP) in Europe, for the percentage of subjects achieving seroprotection and seroconversion [29, 30] . Previously reported results from phase 2 studies with another MDCK cell culture-derived TIV have demonstrated the experimental vaccine to be well tolerated and immunogenic in children, healthy adults, and seniors [12] . Similarly, another MDCK cell culture-derived experimental vaccine has fulfilled CHMP serologic criteria for the licensure of seasonal influenza vaccines [13] . None of these studies, however, were designed to show statistical noninferiority.
Inactivated influenza vaccines have a long history of safety and efficacy. The demand for influenza vaccines in the United States has significantly increased in recent years because of greater emphasis on annual vaccination and a marked expansion of the number of individuals recommended for vaccination, especially in the pediatric population (6 months through 18 years of age) [31] . The fragility and unpredictability of the vaccine-production supply chain underscores the need for alternative manufacturing methods to meet future increasing demands. Mammalian cell culture-derived vaccines may be able to address this supply problem [11-13, 24, 32] .
The MDCK cell line successfully supports influenza virus growth and is the most well-known and accepted cell substrate in which to isolate, grow, and study influenza viruses. Almost all influenza virus surveillance is conducted via isolation in cell cultures, and characterization for surveillance and selection of vaccine virus candidates in World Health Organization labo-ratories is performed using MDCK cells. Furthermore, in comparison with other cell lines (such as Vero cells), MDCK cells have been found to have superior growth properties for influenza virus strains A and B [24] . Ultimately, however, demonstration of the safety of the MDCK cell line and of vaccine tolerability will be key to the future application of the cell line.
The safety of the MDCK cell line has been evaluated extensively; in vivo studies have proved the MDCK cells, cell lysates, and DNA to be nononcogenic, and no adventitious agents have been detected in the MDCK cell line. Furthermore, the vaccine manufacturing process has been shown to be capable of removing all intact MDCK cells and reducing MDCK cell DNA levels to !10 ng per vaccine dose [25] .
Concerns over the viral safety of vaccines have also arisen from the potential incidental introduction of adventitious agents into the vaccine manufacturing process [26, 27] . Studies have shown that the use of MDCK cells to propagate vaccine virus from egg-isolated influenza virus strains does not introduce new or greater adventitious virus risk, compared with eggbased vaccine production [28] . Indeed, the production process can reduce the level of any adventitious agent to one that is unable to cause infection [22] . Additionally, in vivo studies have shown that none of the dead cells, cell extracts, or isolated DNA in the growth medium were tumorigenic or oncogenic in immunosuppressed or immunocompetent animals [25] .
Cell culture technology offers a number of practical advantages over egg-based influenza vaccine production that potentially make it a preferable system. Cell culture technology significantly reduces lead times and provides greater flexibility and viability of production because of the elimination of reliance on egg availability. Cell stocks can be stored frozen, and large quantities of vaccine can be generated on short notice [17, 33] . This would be particularly advantageous in a pandemic situation, when demand for vaccine would increase with little or no warning; cell stocks could be defrosted and production started immediately. For egg-based vaccine production, however, notice of up to 1 year is needed to ensure egg availability.
Furthermore, future use of MDCK cells to produce the seed virus would enable the growth of avian strains, such as A/H5N1, without adaptation. In addition, a vaccine virus that is grown in a cell culture system is more similar to wild-type virus. In contrast, egg-based vaccine viruses are often adapted to grow in chicken eggs, which may alter their hemagglutinin-binding specificities. Influenza virus isolates derived from MDCK cells have been shown to possess hemagglutinin antigens indistinguishable from those of natural, uncultivated virus [19, 34, 35] . Moreover, CCIV could provide a much-needed alternative for individuals with egg allergies, for whom the currently available influenza vaccines are contraindicated.
Our findings indicate that the safety, tolerability, and immunogenicity profiles of CCIV are comparable to those of TIV; however, this study has some limitations that need to be considered when extrapolating the results. The results may not be applicable to other populations, such as children and seniors. Antibody levels have been used as a surrogate marker for efficacy, and future efficacy and effectiveness studies may confirm our results. However, the study also has important strengths: the groups were comparable demographically, and the sample size was sufficiently large to provide validation of these findings.
Influenza vaccines derived from cell culture represent a significant advance and could provide protection against this serious infectious disease.
